Here’s a hard truth: relying solely on medications for long-term weight control might be setting you up for disappointment. But here’s where it gets controversial—while weight-loss drugs can deliver impressive initial results, a groundbreaking study reveals that most people regain nearly all the weight they lost within two years of stopping the medication. And this isn’t just about the numbers on the scale; it’s about the return of health risks like diabetes and heart disease, which creep back in just as quickly.
The study, published in The BMJ (https://www.bmj.com/content/392/bmj-2025-085304), analyzed 37 trials involving over 9,000 participants who used weight-loss medications, including GLP-1 receptor agonists, for at least two months. The findings are eye-opening: patients regained an average of 0.4 kilograms per month after discontinuing the drugs, with weight returning almost four times faster than it would after traditional diet and exercise changes. And this is the part most people miss—even if you’ve shed a significant amount of weight during treatment, the rate of regain is shockingly consistent, regardless of how much you initially lost.
For GLP-1 medications, the data only extends to one year post-treatment, but the projections are clear: without ongoing intervention, the benefits fade fast. Researchers caution that these drugs, while effective in the short term, should not be seen as a standalone solution. Instead, they emphasize the need for long-term strategies that combine medication with behavioral support, lifestyle changes, and realistic treatment plans.
Dr. Trevor Steward, a senior research fellow at the University of Melbourne, notes that this study confirms what many doctors have observed in practice: weight often returns once patients stop taking the medication. ‘The high cost, side effects, and inconvenience of ongoing injections are just a few reasons people discontinue,’ he explains. ‘Medications should be part of a broader approach, not a quick fix.’
Here’s the kicker: as interest in weight-loss medications skyrockets globally—with one in eight Americans using injectable GLP-1 drugs (https://www.abc.net.au/news/2025-12-23/wegovy-pill-approved-in-us-new-obesity-treatment/106175652) and hundreds of thousands of Australians paying up to $5,000 annually for private prescriptions (https://www1.racgp.org.au/newsgp/clinical/pbac-weight-loss-drug-decision-imminent)—the study raises urgent questions about their long-term value. In Australia, the Federal Government is considering adding GLP-1 drugs like semaglutide (sold as Wegovy) to the Pharmaceutical Benefits Scheme, following a recommendation late last year (https://www1.racgp.org.au/newsgp/clinical/wegovy-recommended-for-pbs-listing).
Associate Professor Dominika Kwasnicka, also from the University of Melbourne, warns that expanding access to these medications without comprehensive follow-up could lead to short-term gains followed by long-term disappointment. ‘We need to embed pharmacotherapy within long-term care models that include behavioral support, continuity of care, and honest conversations about treatment duration,’ she says. ‘Viewing these drugs as temporary fixes is a recipe for failure.’
Now, here’s the question that’ll spark debate: Are weight-loss medications worth the investment if their benefits disappear so quickly? Or should we focus on developing sustainable, holistic approaches that address the root causes of weight gain? Let us know your thoughts in the comments—this is a conversation that’s just getting started.
